loading page

BIOLOGICAL TREATMENTS IN ALLERGY: PRESCRIPTION AND MANAGEMENT OF HYPERSENSITIVITY REACTIONS
  • +19
  • Leyla Barakat,
  • María José Torres,
  • Elizabeth J. Phillips,
  • Marco Caminati,
  • Yoon-Seok Chang,
  • Davide Caimmi,
  • Mario Sanchez-Borges,
  • Lanny Rosenwasser,
  • Alain Didier,
  • Frédéric De Blay,
  • Jean-François fontaine,
  • Isabelle Bosse,
  • Sébastien lefevre,
  • Cintia Bassani,
  • Maria di Filippo,
  • Ignacio J Ansotegui,
  • Mário Morais-Almeida,
  • Motohiro Ebisawa,
  • Bryan Martin,
  • Bernard Thong,
  • Pascal Demoly,
  • LUCIANA TANNO
Leyla Barakat
University Hospital Centre Montpellier
Author Profile
María José Torres
Universidad de Málaga Facultad de Medicina
Author Profile
Elizabeth J. Phillips
Vanderbilt University School of Medicine
Author Profile
Marco Caminati
Verona University Hospital
Author Profile
Yoon-Seok Chang
Seoul National University Bundang Hospital
Author Profile
Davide Caimmi
Department of respiratory medicine and allergy, Hôpital Arnaud de Villeneuve, CHU Montpellier, Univ Montpellier
Author Profile
Mario Sanchez-Borges
Centro Medico-Docente La Trinidad
Author Profile
Lanny Rosenwasser
Children's Mercy Hospitals and Clinics
Author Profile
Alain Didier
CHU Toulouse
Author Profile
Frédéric De Blay
University Hospital Strasbourg
Author Profile
Jean-François fontaine
Allergist
Author Profile
Isabelle Bosse
Allergist
Author Profile
Sébastien lefevre
Universite de Lorraine
Author Profile
Cintia Bassani
IMED School of Medicine
Author Profile
Maria di Filippo
University of Pavia
Author Profile
Ignacio J Ansotegui
Hospital Quironsalud Bizkaia
Author Profile
Mário Morais-Almeida
CUF-Descobertas Hospital
Author Profile
Motohiro Ebisawa
National Hospital Organization, Sagamihara National Hospital
Author Profile
Bryan Martin
Columbus State University
Author Profile
Bernard Thong
Tan Tock Seng Hospital
Author Profile
Pascal Demoly
University Hospital of Montpellier
Author Profile
LUCIANA TANNO
Hospital Sírio Libanês
Author Profile

Abstract

Background: Allergy is witnessing major advances, in particular with the advent of biological therapies for treating allergic diseases. Given the novelty of these therapeutics, we aimed to explore by a worldwide survey, the prescription and the management of hypersensitivity reactions (HR) of biological agents (BA) in Allergy. Method: We built up an anonymous online questionnaire, sent out by mail and social media and circulated for 40 days. Results: 348 responses were from 59 countries, with a majority from Europe (62.6%). 97% of responders practiced allergy and 48.5%, exclusively so. Allergy was mentioned as a full specialty in 69.5 % of cases. 71% of responders confirmed the right of prescription of BA for allergists in their country and 78.4 % prescribed BA in their clinical practice. Europe included almost all the allergists who did not have the right of prescribing BA (95.5%), specifically France (91%). The most prescribed BA were Anti IgE (78.1%) and anti IL5 (43.9%). The most declared HR to BA were local reactions (74.1%) followed by anaphylaxis like symptoms (6.8%) and delayed exanthemas (5.1%). Desensitization was considered in 18.9% of cases. These HR were reported in 48.8% of cases. Conclusion: Although BA are now a pillar in the treatment of allergic diseases and allergists are familiar with management of HR associated with BA, their prescription is not authorized for allergists in all countries. BA showed to be generally safe but HR, which may be severe, could occur with a lack of consensus on the management.